Section Arrow
Quote
RANI.NASDAQ
- Rani Therapeutics Holdings
(Financial Status)
Quotes are at least 15-min delayed:2025/07/22 19:22 EDT
After Hours
Last
 0.4261
-0.0113 (-2.58%)
Bid
0.4242
Ask
0.4307
High 0.44 
Low 0.4201 
Volume 8769 
Regular Hours
Last
 0.4374
+0.0174 (+4.14%)
Day High 
0.45 
Prev. Close
0.42 
1-M High
0.8659 
Volume 
1.97M 
Bid
0.4242
Ask
0.4307
Day Low
0.416 
Open
0.416 
1-M Low
0.387 
Market Cap 
16.48M 
Currency USD 
P/E -- 
%Yield -- 
10-SMA 0.54 
20-SMA 0.53 
50-SMA 0.57 
52-W High 3.75 
52-W Low 0.387 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-0.98/-0.51
Enterprise Value
29.73M
Balance Sheet
Book Value Per Share
-0.08
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
1.03M
Operating Revenue Per Share
--
Industry Comparison
More
Code Name   Last Change Change (%) P/E P/E Range
NCNANuCana plc0.053+0.002+3.92%-- 
After Hours 0.0527 -0.0003 -0.57%
PLRZPolyrizon Ltd1.45+0.5422+59.73%-- 
After Hours 1.94 +0.49 +33.79%
REPLReplimune Group2.805-9.52-77.24%-- 
After Hours 2.79 -0.015 -0.53%
IOVAIovance Biotherapeutics3.13+0.64+25.70%-- 
After Hours 3.25 +0.12 +3.83%
TNFATNF Pharmaceuticals Inc.0.107-0.0224-17.31%-- 
After Hours 0.1086 +0.0016 +1.50%
Quotes are at least 15-min delayed：2025/07/22 19:22 EDT
Industry overview quotes are at least 15 minutes delayed
Business Description
Rani Therapeutics Holdings Inc is a clinical-stage biotherapeutics company advancing technologies to enable the development of orally administered biologics to provide patients, physicians, and healthcare systems with a convenient alternative to painful injections. The company has developed the RaniPill capsule, which is designed to deliver a wide variety of drug substances, including antibodies, proteins, peptides, and oligonucleotides. RaniPill is a proprietary and patented platform technology, intended to replace subcutaneous or IV injection of biologics with oral dosing. The company is also engaged in developing RaniPill HC, which is intended to enable the delivery of drug payloads in liquid form with high bioavailability.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.